The use of Cav rather than AUC in safety assessment

Regulatory Toxicology and Pharmacology

Volumn 57, Issue 1, 2010, Pages 70-73

  Smith, D A ^a   Morgan, P ^a   Vogel, W M ^b   Walker, D K ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

AUC; Buspirone; Cav; Cmax; Phenytoin; Sildenafil; Toxicokinetics; Zatosetron

Indexed keywords

BUSPIRONE; ONDANSETRON; PHENYTOIN; SEROTONIN ANTAGONIST; SILDENAFIL; ZATOSETRON;

ABNORMAL FECES; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; ERECTILE DYSFUNCTION; FETAL HYDANTOIN SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; NEUROTOXICITY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REFERENCE VALUE; RISK ASSESSMENT; SALIVATION; SPECIES COMPARISON; TOXICOKINETICS; VISUAL DISORDER; VOMITING;

ANIMALS; AREA UNDER CURVE; CONSUMER PRODUCT SAFETY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TIME FACTORS; TOXICITY TESTS;

EID: 77951978113     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.01.001     Document Type: Article

References (19)

1. Abbott D., Comby P., Charuel C., Graepel P., Hanton G., Leblancc B., Ladola A., Longeart L., Paulus G., Peters C., Stadler J. Preclinical safety profile of sildenafil. Int. J. Impot. Res. 2004, 16:498-504.
2. 3 receptor antagonist, in rhesus monkeys. Drug Chem. Toxicol. 1995, 18:61-82.
3. Cavero I. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Expert Opin. Drug Saf. 2007, 6:465-471.
4. Celio L., Denaro A., Canova S., Gevorgyan A., Bajetta E. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 2008, 94:447-452.
5. Cohen M.L., Bloomquist W., Schmid C.R., Robertson D.W., Wong D.T. Zatosetron, a selective 5-HT3 receptor antagonist: pharmacological activities of human and animal metabolites. Drug Dev. Res. 1993, 29:209-215.
6. Danielsson B., Skold A.C., Azarbayjani F., Ohman I., Webster W. Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to fetal hydantoin syndrome in rats. Toxicol. Appl. Pharmacol. 2000, 163:164-175.
7. Danielsson B.R., Skold A.C., Azarbayjani F. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr. Pharm. Des. 2001, 7:787-802.
8. Danielsson B.R., Landsell K., Patmore L., Tomson T. Phenytoin and phenobarbitol inhibit human HERG potassium channels. Epilepsy Res. 2003, 55:147-157.
9. 3) receptor antagonist, in humans. Drug Metab. Dispos. 1993, 21:249-254.
10. 3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 2002, 7:424-436.
11. Kuryshev Y.A., Brown A.M., Wang L., Benedict C.R., Rampe D. Interactions of 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J. Pharmacol. Exp. Ther. 2000, 295:614-620.
12. Marathe P.H., Shen F., Markham P., Greene D.S. Pharmacokinetics of buspirone following oral administration to rhesus monkeys. J. Pharm. Pharmacol. 1999, 51:601-607.
13. Sanger G.J. 5-Hydroxytryptamine and the gastrointestinal tract: where next?. Trends Pharmacol. Sci. 2008, 29:465-471.
14. Smith W.T., Londborg P.D., Blomgren S.L., Tollefson G.D., Sayler M.E. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J. Clin. Psychopharmacol. 1999, 19:125-131.
15. van der Graaf, P., Holbrook, M., Wallis, R., 2008. Application of translational pharmacokinetic-pharmacodynamic (PKPD) modelling and simulation to preclinical safety testing. Preclinical World 2008, pp. 10-12. Available from: http://www.sovereign-publications.com/pcw.htm.
16. 1A receptor antagonist, using a behavioural model in rats. Eur. J. Pharmacol. 2001, 414:233-343.
17. Wallis R.M. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Nippon Yakurigaku Zasshi 1999, 114:22P-26P.
18. 3 receptor antagonists, in anesthetised dogs. Drug Dev. Res. 1991, 24:277-284.
19. 1A receptor occupancy in rats. Drug Metab. Dispos. 2007, 35:1387-1392.